OBJECTIVE: To determine relationship of echocardiographic measures of pulmonary hypertension to lung function and inflammatory biomarkers in HIV-infected individuals. DESIGN: Cross-sectional study of 116 HIV-infected outpatients. METHODS: Doppler-echocardiography and pulmonary function testing were performed. Induced sputum and plasma cytokines, sputum cell counts and differentials, markers of peripheral T-cell activation, and serum N-terminal pro-brain natriuretic peptide (NT-proBNP) were measured. Univariate and multivariate analyses determined relationship of echocardiographic variables to pulmonary function, inflammation, and NT-proBNP. RESULTS: Mean estimated pulmonary artery systolic pressure (PASP) was 34.3 mmHg (SD 6.9) and mean tricuspid regurgitant jet velocity (TRV) was 2.5 m/s (SD 0.32). Eighteen participants (15.5%) had PASP of at least 40 mmHg, and nine (7.8%) had TRV of at least 3.0 m/s. Elevated TRV was significantly associated with CD4 cell counts below 200 cells/μl and higher log HIV-RNA levels. Forced expiratory volume in 1 s (FEV(1)) percentage predicted, FEV(1)/forced vital capacity, and diffusing capacity for carbon monoxide (DLco) percentage predicted were significantly lower in those with elevated PASP or TRV. Sputum interleukin-8, peripheral interleukin-8, peripheral interferon-γ levels, and CD8(+) T-cell expression of CD69(+) were associated with increasing PASP and TRV. Log NT-proBNP was significantly higher with increasing PASP and TRV. Left ventricular function was not associated with PASP or TRV. CONCLUSION: Echocardiographic manifestations of pulmonary hypertension are common in HIV and are associated with respiratory symptoms, more advanced HIV disease, airway obstruction, abnormal DLco, and systemic and pulmonary inflammation. Pulmonary hypertension and chronic obstructive pulmonary disease coexist in HIV and may arise secondary to common inflammatory mechanisms.
OBJECTIVE: To determine relationship of echocardiographic measures of pulmonary hypertension to lung function and inflammatory biomarkers in HIV-infected individuals. DESIGN: Cross-sectional study of 116 HIV-infected outpatients. METHODS: Doppler-echocardiography and pulmonary function testing were performed. Induced sputum and plasma cytokines, sputum cell counts and differentials, markers of peripheral T-cell activation, and serum N-terminal pro-brain natriuretic peptide (NT-proBNP) were measured. Univariate and multivariate analyses determined relationship of echocardiographic variables to pulmonary function, inflammation, and NT-proBNP. RESULTS: Mean estimated pulmonary artery systolic pressure (PASP) was 34.3 mmHg (SD 6.9) and mean tricuspid regurgitant jet velocity (TRV) was 2.5 m/s (SD 0.32). Eighteen participants (15.5%) had PASP of at least 40 mmHg, and nine (7.8%) had TRV of at least 3.0 m/s. Elevated TRV was significantly associated with CD4 cell counts below 200 cells/μl and higher log HIV-RNA levels. Forced expiratory volume in 1 s (FEV(1)) percentage predicted, FEV(1)/forced vital capacity, and diffusing capacity for carbon monoxide (DLco) percentage predicted were significantly lower in those with elevated PASP or TRV. Sputum interleukin-8, peripheral interleukin-8, peripheral interferon-γ levels, and CD8(+) T-cell expression of CD69(+) were associated with increasing PASP and TRV. Log NT-proBNP was significantly higher with increasing PASP and TRV. Left ventricular function was not associated with PASP or TRV. CONCLUSION: Echocardiographic manifestations of pulmonary hypertension are common in HIV and are associated with respiratory symptoms, more advanced HIV disease, airway obstruction, abnormal DLco, and systemic and pulmonary inflammation. Pulmonary hypertension and chronic obstructive pulmonary disease coexist in HIV and may arise secondary to common inflammatory mechanisms.
Authors: N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger Journal: J Am Soc Echocardiogr Date: 1989 Sep-Oct Impact factor: 5.251
Authors: W L Henry; A DeMaria; R Gramiak; D L King; J A Kisslo; R L Popp; D J Sahn; N B Schiller; A Tajik; L E Teichholz; A E Weyman Journal: Circulation Date: 1980-08 Impact factor: 29.690
Authors: M Patricia George; Hunter C Champion; Mark T Gladwin; Karen A Norris; Alison Morris Journal: Am J Respir Crit Care Med Date: 2012-06-01 Impact factor: 21.405
Authors: Matthew R Gingo; Mehdi Nouraie; Cathy J Kessinger; Ruth M Greenblatt; Laurence Huang; Eric C Kleerup; Lawrence Kingsley; Deborah K McMahon; Alison Morris Journal: Ann Am Thorac Soc Date: 2018-02
Authors: Carl D Koch; Mark T Gladwin; Bruce A Freeman; Jon O Lundberg; Eddie Weitzberg; Alison Morris Journal: Free Radic Biol Med Date: 2016-12-16 Impact factor: 7.376
Authors: Matthew R Gingo; Jiayan He; Catherine Wittman; Carl Fuhrman; Joseph K Leader; Cathy Kessinger; Lorrie Lucht; William A Slivka; Yingze Zhang; Deborah K McMahon; Frank C Sciurba; Alison Morris Journal: Eur Respir J Date: 2013-02-21 Impact factor: 16.671
Authors: Alison Morris; Meghan Fitzpatrick; Marnie Bertolet; Shulin Qin; Lawrence Kingsley; Nicolas Leo; Cathy Kessinger; Heather Michael; Deborah Mcmahon; Renee Weinman; Stephen Stone; Joseph K Leader; Eric Kleerup; Laurence Huang; Stephen R Wisniewski Journal: AIDS Date: 2017-02-20 Impact factor: 4.177